GRAIL announces FDA advisory committee review of Galleri test
The Molecular and Clinical Genetics Panel will meet on September 23, 2026, to review GRAIL's Premarket Approval application for the Galleri blood test.
See the latest news and media coverage for GRAIL. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company focused on early cancer detection
grail.comLast updated
In short: GRAIL reported strong Q2 2026 growth, secured $110 million in financing, and prepared for a critical FDA review of its Galleri test.
The Molecular and Clinical Genetics Panel will meet on September 23, 2026, to review GRAIL's Premarket Approval application for the Galleri blood test.
Total revenue grew 26% to $44.7 million, Galleri volume rose 35% to 61,000, net loss was $110.2 million, and Samsung financing closed.
The investment strengthens GRAIL's balance sheet and supports international expansion for Galleri.
The early analysis showed promising performance but not enough to accelerate implementation. The decision will be based on final results expected in 2026.
The company behind the colorectal cancer blood test Colvera has hit biotechnology company Grail Inc. with a lawsuit in Delaware federal court claiming the latter's...
FDA approval for its multi-cancer early detection test, Galleri, would strengthen the case for the...
Multi-cancer early detection test company Grail ( GRAL +0.07%) stock rose 15.8% in August, according to data from S&P Global Market Intelligence. However, the move...
Amazon.com Inc. (ticker: AMZN) founder and tech industry icon Jeff Bezos is closely followed for his forward-thinking approach — as well as his mammoth fortune...
Track GRAIL and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to GRAIL and other trending companies.